Altamira Therapeutics Ltd. (CYTOF)
OTCMKTS · Delayed Price · Currency is USD
0.0716
0.00 (0.00%)
At close: Sep 21, 2026
Altamira Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Selling, General & Admin | 2.45 | 3.19 | 3.48 | 3.56 | 4.02 | 2.98 |
Research & Development | 3.23 | 3.73 | 3.38 | 2.39 | 1.83 | 3.2 |
Other Operating Expenses | -0.12 | -0.07 | -0.27 | -0.01 | 0 | -0.2 |
Operating Expenses | 5.56 | 6.85 | 6.58 | 5.94 | 5.86 | 5.97 |
Operating Income | -5.56 | -6.85 | -6.58 | -5.94 | -5.86 | -5.97 |
Interest Expense | -0.05 | -0.02 | -1.15 | -0.95 | -0.02 | -0.15 |
Interest & Investment Income | 0 | 0 | 0.34 | 0.12 | 0.03 | 0 |
Earnings From Equity Investments | -1.07 | -0.77 | -0.04 | - | - | - |
Currency Exchange Gain (Loss) | 1.25 | -0.58 | -0.5 | -0.32 | 0.05 | -0.38 |
Other Non Operating Income (Expenses) | -0.24 | -0.24 | -0.18 | 0.47 | 0.01 | -2.79 |
EBT Excluding Unusual Items | -5.67 | -8.46 | -8.12 | -6.62 | -5.79 | -9.29 |
Asset Writedown | - | - | - | -12.92 | -1.68 | - |
Other Unusual Items | 0.01 | - | 0.03 | - | - | - |
Pretax Income | -5.65 | -8.46 | -8.09 | -19.54 | -7.47 | -9.29 |
Income Tax Expense | - | - | - | -0.01 | -0.13 | -0.02 |
Earnings From Continuing Operations | -5.65 | -8.46 | -8.09 | -19.53 | -7.34 | -9.27 |
Earnings From Discontinued Operations | - | - | 3.79 | -8.25 | -11.38 | - |
Net Income | -5.65 | -8.46 | -4.31 | -27.78 | -18.71 | -9.27 |
Net Income to Common | -5.65 | -8.46 | -4.31 | -27.78 | -18.71 | -9.27 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 4 | 3 | 0 | 0 | 0 | 0 |
Shares Outstanding (Diluted) | 4 | 3 | 0 | 0 | 0 | 0 |
Shares Change | 204.28% | 476.54% | 978.83% | 37.51% | 120.26% | - |
EPS (Basic) | -1.31 | -2.99 | -8.77 | -610.03 | -565.06 | -616.45 |
EPS (Diluted) | -1.31 | -2.99 | -8.77 | -610.03 | -565.06 | -616.45 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Free Cash Flow | -4.4 | -6.22 | -12.81 | -9.09 | -15 | -5.47 |
Free Cash Flow Per Share | -1.02 | -2.19 | -26.08 | -199.68 | -452.91 | -364.11 |
EBITDA | - | - | - | -5.89 | -5.81 | -5.95 |
D&A For EBITDA | - | - | - | 0.05 | 0.05 | 0.02 |
EBIT | -5.56 | -6.85 | -6.58 | -5.94 | -5.86 | -5.97 |